Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and PK of [14C]XZP-3621 in Healthy Male Subjects
NCT05836805Phase 1Unknown
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- May 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dirozalkib in non-small cell lung cancer (NSCLC), sponsored by Xuanzhu Biopharmaceutical. Primary endpoints: Total recovery of radioactivity in urine and feces at 19 days, Radioactivity concentration of each plasma sample at 19 days and 4 more. Status: unknown.
02
Drugs
dirozalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05836805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05836805.